Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. (0RGI.L) Financial Performance & Income Statement Overview
Review Cosmo Pharmaceuticals N.V. (0RGI.L) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Cosmo Pharmaceuticals N.V. (0RGI.L) Income Statement & Financial Overview
Analyze Cosmo Pharmaceuticals N.V.’s 0RGI.L earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $130.55M | $136.24M | $24.56M | $24.56M |
| Cost of Revenue | -$3.29M | $23.15M | $10.23M | $10.23M |
| Gross Profit | $133.84M | $113.09M | $14.32M | $14.32M |
| Gross Profit Ratio | $1.03 | $0.83 | $0.58 | $0.58 |
| R&D Expenses | -$10.45M | $10.82M | $5.26M | $5.26M |
| SG&A Expenses | -$8.91M | $16.32M | $10.49M | $10.49M |
| Operating Expenses | $71.91M | $26.13M | $14.65M | $14.65M |
| Total Costs & Expenses | $68.62M | $49.28M | $24.88M | $24.88M |
| Interest Income | $726000.00 | $943000.00 | $750000.00 | $750000.00 |
| Interest Expense | $53000.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $4.99M | $7.29M | $3.32M | $3.32M |
| EBITDA | $71.46M | $94.25M | $2.83M | $2.83M |
| EBITDA Ratio | $0.55 | $0.69 | $0.12 | $0.12 |
| Operating Income | $61.93M | $86.95M | -$488500.00 | -$488500.00 |
| Operating Income Ratio | $0.47 | $0.64 | -$0.02 | -$0.02 |
| Other Income/Expenses (Net) | $2.69M | $1.79M | -$582000.00 | -$582000.00 |
| Income Before Tax | $64.62M | $88.75M | -$1.07M | -$1.07M |
| Income Before Tax Ratio | $0.49 | $0.65 | -$0.04 | -$0.04 |
| Income Tax Expense | $7.49M | $12.69M | $2.04M | $2.04M |
| Net Income | $57.24M | $75.99M | -$3.21M | -$3.21M |
| Net Income Ratio | $0.44 | $0.56 | -$0.13 | -$0.13 |
| EPS | $3.44 | $4.71 | -$0.20 | -$0.20 |
| Diluted EPS | $3.41 | $4.71 | -$0.20 | -$0.20 |
| Weighted Avg Shares Outstanding | $16.36M | $16.15M | $16.06M | $16.06M |
| Weighted Avg Shares Outstanding (Diluted) | $16.42M | $16.15M | $16.06M | $16.06M |
Over the last four quarters, Cosmo Pharmaceuticals N.V. achieved steady financial progress, growing revenue from $24.56M in Q3 2023 to $130.55M in Q4 2024. Gross profit stayed firm with margins at 103% in Q4 2024 versus 58% in Q3 2023. Operating income totaled $61.93M in Q4 2024, maintaining a 47% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $71.46M. Net income dropped to $57.24M, with EPS at $3.44. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan